Fig. 4From: Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsRisk factors in acute myeloid leukemia with extramedullary manifestations. Among AML patients bearing extramedullary manifestations (EM) mutations of TP53 and IKZF1 were rare (7/225 [3.1%] and 9/225 [4.0%], respectively). However, EM AML patients with TP53 mutations showed significantly decreased event-free (A) and overall survival (B). Likewise, EM AML patients with IKZF1 mutations also showed significantly decreased event-free (C) and overall survival (D)Back to article page